Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 9:20 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 11,405 matching trials from the live ClinicalTrials.gov search.

Filters: Seattle, Washington Clear all

Conditions: Colorectal Cancer
Interventions: AZD6244, Irinotecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 12
States / cities: Los Angeles, California • Palm Springs, California • Aurora, Colorado + 9 more

Conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: melphalan, recombinant interferon alfa, aldesleukin, in vitro-treated peripheral blood stem cell transplantation; Drug · Biological · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 69 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Myeloma
Interventions: Biospecimen Collection, Dietary Intervention, Medical Chart Review, Questionnaire Administration; Procedure · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Edivoxetine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Years to 18 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 16
States / cities: Spring Valley, California • Gainesville, Florida • Orlando, Florida + 13 more

Conditions: Prostate Cancer
Interventions: Abiraterone acetate, Dutasteride, Prednisone; Drug
Lead sponsor: Mary-Ellen Taplin, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 4
States / cities: Boston, Massachusetts • Seattle, Washington

Conditions: Wilson Disease
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 4
States / cities: New Haven, Connecticut • Orlando, Florida • Houston, Texas + 1 more

Conditions: Lymphoma, Follicular, Lymphoma, Mantle-Cell, Marginal Zone Lymphoma, Primary Mediastinal B-cell Lymphoma, Diffuse Large B Cell Lymphoma, Lymphoma, Non-Hodgkin
Interventions: ADI-001, Fludarabine, Cyclophosphamide; Genetic · Drug
Lead sponsor: Adicet Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 10
States / cities: Stanford, California • Miami, Florida • Atlanta, Georgia + 7 more

Conditions: Locally Advanced or Metastatic Urothelial Carcinoma
Interventions: Avelumab, Sacituzumab Govitecan (SG), M6223, NKTR-255, JB100; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 256 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 8
States / cities: Coeur d'Alene, Idaho • Kansas City, Kansas • Baltimore, Maryland + 4 more

Conditions: Primary Progressive Multiple Sclerosis
Interventions: FTY720, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 25 Years to 65 Years
Enrollment: 970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 33
States / cities: Newport Beach, California • Sacramento, California • Aurora, Colorado + 29 more

Conditions: Melanoma
Interventions: Pembrolizumab, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 12 Years and older
Enrollment: 976 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2033
U.S. locations: 39
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 28 more

Conditions: Atopic Dermatitis
Interventions: ADX-914, Placebo; Drug
Lead sponsor: Q32 Bio Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 24
States / cities: Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 20 more

Conditions: Cystic Fibrosis
Interventions: ELX/TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more

Conditions: Parenteral Nutrition Associated Liver Disease (PNALD), Essential Fatty Acid Deficiency, Malnutrition, Pediatric ALL
Interventions: Omegaven® (fish oil triglycerides) Injectable Emulsion; Drug
Lead sponsor: Fresenius Kabi; Industry
Eligibility: 1 Day to 17 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 10
States / cities: Fountain Valley, California • Los Angeles, California • Chicago, Illinois + 7 more

Conditions: Post-Operative Atrial Fibrillation
Interventions: AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems, Anticoagulation Therapy; Device · Drug
Lead sponsor: AtriCure, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 562 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 22
States / cities: San Diego, California • Stanford, California • Orlando, Florida + 15 more

Conditions: Lower Limb Amputation Below Knee
Interventions: As-prescribed stiffness, Two categories stiffer than the as-prescribed stiffness, Two categories less stiff than the as-prescribed stiffness; Device
Lead sponsor: Seattle Institute for Biomedical and Clinical Research; Other
Eligibility: 18 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Substance Abuse, Juvenile Delinquency, Sexual Behavior, Criminal Behavior, Violence, Depression, Anxiety, Suicide, Sexually Transmitted Infection, Educational Attainment
Interventions: Communities That Care; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 10 Years and older
Enrollment: 52,323 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Surgery
Interventions: Electronic Medical Record Based Discharge Medication Order Set; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Pain, Burn
Interventions: Virtual Reality Distraction, Audio (sound of nature), Control standard nurse wound care; Behavioral
Lead sponsor: National Institute of General Medical Sciences (NIGMS); NIH
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Syphilis
Interventions: Lumbar puncture; Procedure
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Non-Small Cell Lung Cancer
Interventions: INC280 single agent, erlotinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Los Angeles, California • Orange, California • Detroit, Michigan + 2 more

Conditions: Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
Interventions: Not listed
Lead sponsor: Arbor Research Collaborative for Health; Other
Eligibility: 18 Years to 90 Years
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2030
U.S. locations: 46
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Burbank, California + 39 more

Conditions: Dermatitis, Atopic
Interventions: Dupilumab, Placebo (for Dupilumab); Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 708 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 53
States / cities: Anniston, Alabama • Birmingham, Alabama • Phoenix, Arizona + 50 more

Conditions: HIV, HBV
Interventions: E/C/F/TAF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 21
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more

Conditions: Prostate Cancer
Interventions: NanoTherm Ablation; Device
Lead sponsor: MagForce USA; Industry
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Tampa, Florida • Austin, Texas • San Antonio, Texas + 1 more

Search by objective public record fields.

Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec

Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma

A Plant-Based Whole-Foods Meal Delivery Service for Patients With Multiple Myeloma Undergoing Autologous Hematopoietic Cell Transplant

A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder

Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

Natural History of Wilson Disease

A Phase 1 Study of ADI-001 in B Cell Malignancies

A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma (JAVELIN Bladder Medley)

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

AtriClip® Left Atrial Appendage Exclusion Concomitant to Structural Heart Procedures (ATLAS)

Automatic Prosthetic Foot Stiffness Modulation to Improve Balance

The Community Youth Development Study: A Test of Communities That Care

Nudges for Opioid Reduction After Major Surgery Trial

VR High Tech Pain Control Burn Wound Care

Lumbar Puncture and Syphilis Outcome

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Pancreatic Cancer Early Detection Consortium

Study of Dupilumab (REGN668/SAR231893) Monotherapy Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Efficacy and Safety of E/C/F/TAF (Genvoya®) in HIV-1/Hepatitis B Co-infected Adults

Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer